| Bioactivity | Cilastatin sodium (MK0791 sodium) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin sodium inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin sodium is an antibacterial adjunct[1][2][3]. |
| Invitro | Cilastatin (200 μg/mL; 24 hours; RPTECs) treatment protects against Vancomycin-induced proximal tubule apoptosis and increases cell viability, without compromising the antimicrobial effect of Vancomycin[2]. Apoptosis Analysis[2] Cell Line: |
| Name | Cilastatin sodium |
| CAS | 81129-83-1 |
| Formula | C16H25N2NaO5S |
| Molar Mass | 380.43 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen) |
Cilastatin sodium
CAS: 81129-83-1 F: C16H25N2NaO5S W: 380.43
Cilastatin sodium (MK0791 sodium) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μ
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.